Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Vascular and Endovascular Surgery, Velindre University NHS Trust, Health Education and Improvement Wales (HEIW), Cardiff, UK.
J Card Surg. 2022 Nov;37(11):3848-3862. doi: 10.1111/jocs.16918. Epub 2022 Sep 7.
The introduction of the frozen elephant trunk (FET) technique for total arch replacement (TAR) has revolutionized the field of aortovascular surgery. However, although FET yields excellent results, the risk of certain complications requiring secondary intervention remains present, negating its one-step hybrid advantage over conventional techniques. This systematic review and meta-analysis sought to evaluate controversies regarding the incidence of FET-related complications, with a focus on aortic remodeling, distal stent-graft induced new entry (dSINE) and endoleak, in patients with type A aortic dissection (TAAD) and/or thoracic aortic aneurysm.
A comprehensive literature search was conducted using multiple electronic databases including EMBASE, Scopus, and PubMed/MEDLINE to identify evidence on TAR with FET in patients with TAAD and/or aneurysm. Studies published up until January 2022 were included, and after applying exclusion criteria, a total of 43 studies were extracted.
A total of 5068 patients who underwent FET procedure were included. The pooled estimates of dSINE and endoleak were 2% (95% confidence interval [CI] 0.01-0.06, I = 78%) and 3% (95% CI 0.01-0.11, I = 89%), respectively. The pooled rate of secondary thoracic endovascular aortic repair (TEVAR) post-FET was 7% (95% CI 0.05-0.12, I = 89%) while the pooled rate of false lumen thrombosis at the level of stent-graft was 91% (95% CI 0.75-0.97, I = 92%). After subgroup analysis, heterogeneity for distal stent-graft induced new entry (dSINE) and endoleak resolved among European patients, where Thoraflex Hybrid (THP) and E-Vita stent-grafts were used (both I = 0%). In addition, heterogeneity for secondary TEVAR after FET resolved among Asians receiving Cronus (I = 15.1%) and Frozenix stent-grafts (I = 1%).
Our results showed that the FET procedure in patients with TAAD and/or aneurysm is associated with excellent results, with a particularly low incidence of dSINE and endoleak as well as highly favorable aortic remodeling. However the type of stent-graft and the study location were sources of heterogeneity, emphasizing the need for multicenter studies directly comparing FET grafts. Finally, THP can be considered the primary FET device choice due to its superior results.
冷冻象鼻技术(FET)在全主动脉弓置换术(TAR)中的应用彻底改变了血管外科学领域。然而,尽管 FET 取得了优异的结果,但仍存在某些需要二次干预的并发症风险,这否定了其相对于传统技术的一步杂交优势。本系统评价和荟萃分析旨在评估与 FET 相关并发症发生率相关的争议,重点是在主动脉夹层(TAAD)和/或胸主动脉瘤患者中,主动脉重塑、远端支架移植物诱导新入口(dSINE)和内漏。
使用多个电子数据库(包括 EMBASE、Scopus 和 PubMed/MEDLINE)进行全面文献检索,以确定关于 TAAD 和/或动脉瘤患者接受 FET 治疗的 TAR 的证据。纳入截至 2022 年 1 月发表的研究,应用排除标准后,共提取 43 项研究。
共纳入 5068 名接受 FET 手术的患者。dSINE 和内漏的汇总估计值分别为 2%(95%置信区间 [CI] 0.01-0.06,I²=78%)和 3%(95%CI 0.01-0.11,I²=89%)。FET 后二次胸主动脉腔内修复术(TEVAR)的汇总发生率为 7%(95%CI 0.05-0.12,I²=89%),而支架移植物水平的假腔血栓形成的汇总发生率为 91%(95%CI 0.75-0.97,I²=92%)。亚组分析后,欧洲患者中远端支架移植物诱导新入口(dSINE)和内漏的异质性在使用 Thoraflex Hybrid(THP)和 E-Vita 支架的情况下得到解决(均 I²=0%)。此外,接受 Cronus(I²=15.1%)和 Frozenix 支架的亚洲患者 FET 后二次 TEVAR 的异质性得到解决(I²=1%)。
我们的结果表明,TAAD 和/或动脉瘤患者的 FET 手术具有优异的效果,dSINE 和内漏发生率特别低,主动脉重塑效果非常好。然而,支架移植物的类型和研究地点是异质性的来源,强调需要进行直接比较 FET 移植物的多中心研究。最后,由于其卓越的结果,THP 可以被视为主要的 FET 器械选择。